Dr Mercier late-breaking #ESTRO2023 - !!!BLINDED!!! RCT of #radiotherapy for painful bone Mets,
➡️single 8Gy 3DCRT versus SABR 20Gy. ⬆️ complete pain response 54% versus 33% at 3 months with SABR, but not 1 month. Higher rates of re-irradiation in conv RT arm. #radonc
Safety analysis of Northstar trial: Phase II Randomized Study of Osimertinib With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR Mutant NSCLC
👉 excellent safety of surgery & radiotherapy
👉 RT numerically lower tox despite no interruption of Osi in most pts
Excluding people with disabilities from becoming doctors “reductionist thinking that does a disservice to our profession”. What an impressive and eye-opening session. #racma2022
Dr Dinesh Palipana, Doctors With Disability says "we need to think about the communities we serve. 1 in 5 people have a disability. If we are doing the same thing we always have we are not going to go forward." RACMA 2022 - Equity and Access, Healthcare For All #racma2022
Wow! Sublobar resection (including wedge) are equivalent to lobectomy for stage I lung cancer <2cm. No difference in DFS or OS and similar rates of recurrence. #WCLC22
Likely new standard of care!
Practice changing work led by @SunnyD_UT adding evidence to support SRS for small cell lung cancer brain mets. Congrats and thanks for building a great team and for @Sunnybrook to participate. https://t.co/xKocaX6lM5
Delighted to share our systematic review of heart dose
- More stringent IMRT❤️sparing planning objectives needed
- Consensus on contouring and Dose Volume Constraints is lacking
- Dose parameters reported for substructures vary substantially
https://t.co/P4Nu5fPWVX
Great study @leunger22 - would be a game changer. Am assuming you wouldn’t be doing this with concurrent chemo à la PORTEC-3, so patient population might end up being different to those in your study? #gyncsm
Can the number of radiation treatments to the pelvis for uterus cancer patients be decreased from 25 down to 5? See our recent publication in JAMA Oncology - The SPARTACUS trial. #radonc#GynCSM@Sunnybrook@LHSCCanada https://t.co/hgAczLGO1l
Post-hoc analysis of immune-mediated adverse events with durvalumab from PACIFIC in @LungCaJournal. Usually occur in 1st 3m. Most common were pneumonitis and thyroid dysfunction. G3+ were uncommon. Reassuring report led by Dr. @DrJNaidoo et al. #LCSM
https://t.co/pVkCtbgYk0
So excited to attend this year’s Australian Brachytherapy Group’s ASM - very much looking forward to learning from the combined wealth of knowledge from the excellent speakers! @AusBrachy
Are you a Radiation Therapist who’s passionate about research and helping others to do the same? Our newly established Senior Research Radiation Therapist role could be for you 👇 https://t.co/KW8PWH2PcN